TY - JOUR
T1 - Selective Serotonin Reuptake Inhibitor (SSRI) Bleeding Risk
T2 - Considerations for the Consult-Liaison Psychiatrist
AU - McFarland, Daniel
AU - Merchant, Dale
AU - Khandai, Abhisek
AU - Mojtahedzadeh, Mona
AU - Ghosn, Omar
AU - Hirst, Jeremy
AU - Amonoo, Hermioni
AU - Chopra, Depti
AU - Niazi, Shehzad
AU - Brandstetter, Jennifer
AU - Gleason, Andrew
AU - Key, Garrett
AU - di Ciccone, Barbara Lubrano
N1 - Funding Information:
Daniel McFarland, Dale Merchant, Abhisek Khandai, Mona Mojtahedzadeh, Omar Ghosn, Jeremy Hirst, Depti Chopra, Shehzad Niazi, Jennifer Brandstetter, Andrew Gleason, Garrett Key, and Barbara Lubrano di Cicconeeach declare no potential conflicts of interest. Hermioni Amonoo has received a grant from the National Cancer Institute.
Funding Information:
The editors would like to thank Dr. Madhavi-Latha Nagalla for taking the time to review this manuscript. The authors would like to thank the Academy of Consultation-Liaison Psychiatry and its special interest group, Palliative Care & Psycho-Oncology.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023/3
Y1 - 2023/3
N2 - Purpose of Review: To present a clinically oriented review of selective serotonin reuptake inhibitor (SSRI)-related bleeding issues commonly addressed by consult-liaison psychiatrists. Recent Findings: Concomitant medical, surgical, or hospital-based conditions exacerbate the risk of SSRI-related bleeding even though a review of the literature suggests it is only marginally elevated. Psychiatrists and other clinicians need to consider these conditions along with antidepressant benefits when answering the question: to start, hold, continue, or change the antidepressant? Summary: Where an evidence base is limited, mechanistic understanding may help consult-liaison psychiatrists navigate this terrain and collaborate with other medical specialties on responsible antidepressant management. Most often, the risk is cumulative; data are not directly applicable to complex clinical situations. This review incorporates a hematologic perspective and approach to bleeding risk assessment along with extant data on SSRI-induced bleeding risk ad specific medical conditions.
AB - Purpose of Review: To present a clinically oriented review of selective serotonin reuptake inhibitor (SSRI)-related bleeding issues commonly addressed by consult-liaison psychiatrists. Recent Findings: Concomitant medical, surgical, or hospital-based conditions exacerbate the risk of SSRI-related bleeding even though a review of the literature suggests it is only marginally elevated. Psychiatrists and other clinicians need to consider these conditions along with antidepressant benefits when answering the question: to start, hold, continue, or change the antidepressant? Summary: Where an evidence base is limited, mechanistic understanding may help consult-liaison psychiatrists navigate this terrain and collaborate with other medical specialties on responsible antidepressant management. Most often, the risk is cumulative; data are not directly applicable to complex clinical situations. This review incorporates a hematologic perspective and approach to bleeding risk assessment along with extant data on SSRI-induced bleeding risk ad specific medical conditions.
KW - Antidepressant side effects
KW - Bleeding risk
KW - Hemorrhage
KW - Medically complex patients
KW - Serotonin reuptake inhibitor
KW - Thrombocytopenia
UR - http://www.scopus.com/inward/record.url?scp=85146952540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146952540&partnerID=8YFLogxK
U2 - 10.1007/s11920-023-01411-1
DO - 10.1007/s11920-023-01411-1
M3 - Review article
C2 - 36708455
AN - SCOPUS:85146952540
SN - 1523-3812
VL - 25
SP - 113
EP - 124
JO - Current Psychiatry Reports
JF - Current Psychiatry Reports
IS - 3
ER -